USFDA APPROVES DAPAGLIFLOZIN FOR USE IN NON DIABETICS BASED ON DAPA HF

Dear my friends and fellow Colleagues, Here is an update on Dapa HF Trial. Based upon results of DAPA-HF trial, USFDA approves Dapagliflozin for Heart Failure with Reduced Ejection Fraction (HFrEF) in patients with or without Diabetes to reduce the risk of CV death & HHF, Hospitalization for Heart Failure. May, 2020. Regards and thanks, Dr Sepuri Krishna Mohan.

(Edited)

4 Likes

LikeAnswersShare
Yes sir this is latest trial concluded and declared by British heart association It is significant development in treatment of heart failure as well as about dapagliflozin. Yesterday i had discussion on this subject with ADJ of astra zeneca Same conclusion was drawn Thanx for updates
Valuable opinion
0

View 2 other replies

Excellent information sir
Valuable opinion
0
Informative post sir
Thank you doctor
0
Thanks for the update sir
Thank you doctor
0

Cases that would interest you